Stack Suggestions In research protocols, BPC-157 is sometimes studied alongside other compounds investigated for tissue and recovery endpoints, evaluated for additive or complementary effects in controlled settings: BPC-157 TB-500 paired in soft-tissue and recovery research models
Additionally, AOD-9604 does not stimulate IGF-1 production or activate growth hormone receptors, pathways that would otherwise affect appetite-regulating neuropeptides
doi: 10.1155/2016/8473937 143
Because of its ability to promote healing of tendons to bone, nerve protection, and regeneration, and pain reduction at the location of an injury, patients have found BPC-157 to be helpful in treating minor and major injuries, and its a great therapy to consider after surgery to aid in recovery
Schedule: Once-daily subcutaneous injections in 4-week cycles (commonly 4 weeks on, 4 weeks off), repeated as needed